As shown in Figure 6, the administration of BQ 485 (100 nM) can mitigate ET-1-induced arrhythmogenesis of SAN–RA preparations from the MCT-induced PAH group. The gene discussed is EDN1; the disease is pulmonary arterial hypertension.